Abstract
Adoptive transfer of antigen-specific T cells is an attractive means to provide cancer patients with immune cells of a desired specificity and the efficacy of such adoptive transfers has been demonstrated in several clinical trials. Because the T cell receptor is the single specificity-determining molecule in T cell function, adoptive transfer of TCR genes into patient T cells may be used as an alternative approach for the transfer of tumor-specific T cell immunity. On theoretical grounds, TCR gene therapy has two substantial advantages over conventional cellular transfer, as it can circumvent the demanding process of in vitro generation of large numbers of specific immune cells and it allows the use of a set of particularly effective TCR genes in large patient groups. Conversely, TCR gene therapy may be associated with a number of specific problems that are not confronted during classical cellular therapy. Here we review our current understanding of the potential and possible problems of TCR gene therapy, as based on in vitro experiments and mouse model systems. Furthermore, we discuss the prospects of clinical application of this gene therapy approach, and the possible barriers on the route towards clinical use.
Keywords: T cell receptor (TCR), adoptive therapy, gene therapy, T lymphocytes, major histocompatibility complex (MHC)
Current Gene Therapy
Title: Prospects and Limitations of T Cell Receptor Gene Therapy
Volume: 5 Issue: 6
Author(s): Miriam Coccoris, Moniek A. de Witte and Ton. N.M. Schumacher
Affiliation:
Keywords: T cell receptor (TCR), adoptive therapy, gene therapy, T lymphocytes, major histocompatibility complex (MHC)
Abstract: Adoptive transfer of antigen-specific T cells is an attractive means to provide cancer patients with immune cells of a desired specificity and the efficacy of such adoptive transfers has been demonstrated in several clinical trials. Because the T cell receptor is the single specificity-determining molecule in T cell function, adoptive transfer of TCR genes into patient T cells may be used as an alternative approach for the transfer of tumor-specific T cell immunity. On theoretical grounds, TCR gene therapy has two substantial advantages over conventional cellular transfer, as it can circumvent the demanding process of in vitro generation of large numbers of specific immune cells and it allows the use of a set of particularly effective TCR genes in large patient groups. Conversely, TCR gene therapy may be associated with a number of specific problems that are not confronted during classical cellular therapy. Here we review our current understanding of the potential and possible problems of TCR gene therapy, as based on in vitro experiments and mouse model systems. Furthermore, we discuss the prospects of clinical application of this gene therapy approach, and the possible barriers on the route towards clinical use.
Export Options
About this article
Cite this article as:
Coccoris Miriam, de Witte A. Moniek and Schumacher N.M. Ton., Prospects and Limitations of T Cell Receptor Gene Therapy, Current Gene Therapy 2005; 5 (6) . https://dx.doi.org/10.2174/156652305774964730
DOI https://dx.doi.org/10.2174/156652305774964730 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticancer Agents: Towards the Future
Current Medicinal Chemistry - Anti-Cancer Agents Detection of Predictive Markers for Therapeutic Stratification of Salivary Glands Tumors
Current Drug Targets Crocins: The Active Constituents of Crocus Sativus L. Stigmas, Exert Significant Cytotoxicity on Tumor Cells In Vitro
Current Cancer Therapy Reviews Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
Current Clinical Pharmacology Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention
Current Protein & Peptide Science Creating A Standard of Care for Fertility Preservation
Current Women`s Health Reviews The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design Radiosensitizing Potential of Epigenetic Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Endocrine, Metabolic & Immune Disorders - Drug Targets Discovery of Modulators of Protein-Protein Interactions: Current Approaches and Limitations
Current Topics in Medicinal Chemistry Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials
Reviews on Recent Clinical Trials Chromosomal Translocations as Biomarkers in Leukemia Diagnosis and Pharmacogenomics
Recent Patents on Biomarkers Inhibition of PCAF by Anacardic Acid Derivative Leads to Apoptosis and Breaks Resistance to DNA Damage in BCR-ABL-expressing Cells
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Antitarget Therapies: New Frontiers in the Treatment of Cancer)
Anti-Cancer Agents in Medicinal Chemistry Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders
Current Medicinal Chemistry Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design Editorial
Recent Patents on Anti-Cancer Drug Discovery